HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

Abstract
The aim of this study was to establish new biliary tract carcinoma (BTC) cell lines and identify predictive biomarkers for the potential effectiveness of gemcitabine therapy. Surgical specimens of BTC were transplanted directly into immunodeficient mice to establish xenografts, then subjected to in vitro cell culture. The gemcitabine sensitivity of each cell line was determined and compared with the genome-wide gene expression profile. A new predictive biomarker candidate was validated using an additional cohort of gemcitabine-treated BTC cases. From 55 BTC cases, we established 19 xenografts and six new cell lines. Based on their gemcitabine sensitivity, 10 BTC cell lines (including six new and four publicly available ones) were clearly categorized into two groups, and MAGEH1 mRNA expression in the tumor cells showed a significant negative correlation with their sensitivity to gemcitabine. Immunohistochemically, MAGEH1 protein was detected in three (50%) out of six sensitive cell lines, and four (100%) out of four resistant cell lines. In the validation cohort of gemcitabine-treated recurrence cases, patients were categorized into "effective" and "non-effective" groups according to the RECIST guidelines for assessment of chemotherapeutic effects. MAGEH1 protein expression was detected in two (40%) out of five "effective" cases and all four (100%) "non-effective" cases. We have established a new BTC bioresource that covers a wide range of biological features, including drug sensitivity, and is linked with clinical information. Negative expression of MAGEH1 protein serves as a potential predictive marker for the effectiveness of gemcitabine therapy in BTC.
AuthorsHidenori Ojima, Daitaro Yoshikawa, Yoshihiro Ino, Hiroko Shimizu, Masashi Miyamoto, Akiko Kokubu, Nobuyoshi Hiraoka, Noriaki Morofuji, Tadashi Kondo, Hiroaki Onaya, Takuji Okusaka, Kazuaki Shimada, Yoshihiro Sakamoto, Minoru Esaki, Satoshi Nara, Tomoo Kosuge, Setsuo Hirohashi, Yae Kanai, Tatsuhiro Shibata
JournalCancer science (Cancer Sci) Vol. 101 Issue 4 Pg. 882-8 (Apr 2010) ISSN: 1349-7006 [Electronic] England
PMID20088962 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Chemical References
  • Antimetabolites, Antineoplastic
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Deoxycytidine
  • cytoplasmic linker protein 170
  • Gemcitabine
Topics
  • Animals
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Bile Duct Neoplasms (drug therapy, metabolism)
  • Biliary Tract Neoplasms (drug therapy, metabolism)
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Female
  • Gene Expression Profiling
  • Humans
  • Mice
  • Mice, SCID
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Specific Pathogen-Free Organisms
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: